Malaria drug added to cancer therapy in bid to halt liver tumor growth
NCT ID NCT03037437
Summary
This study tested whether adding the drug hydroxychloroquine (HCQ) to the standard liver cancer drug sorafenib could better control advanced liver cancer. It involved 64 patients with cancer not eligible for surgery or transplant. Researchers aimed to see if the drug combination could slow or stop tumor progression more effectively than sorafenib alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Health Cancer Center
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.